Dowling & Yahnke’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.05M | Buy |
49,473
+2,269
| +5% | +$143K | 0.14% | 139 |
|
|
2022
Q2 | $2.92M | Buy |
47,204
+859
| +2% | +$53.2K | 0.14% | 142 |
|
|
2022
Q1 | $2.75M | Sell |
46,345
-1,593
| -3% | -$102K | 0.12% | 157 |
|
|
2021
Q4 | $3.48M | Sell |
47,938
-613
| -1% | -$42.2K | 0.17% | 138 |
|
|
2021
Q3 | $3.39M | Buy |
48,551
+2,143
| +5% | +$151K | 0.19% | 130 |
|
|
2021
Q2 | $3.2M | Buy |
46,408
+1,110
| +2% | +$74.1K | 0.18% | 135 |
|
|
2021
Q1 | $2.93M | Buy |
45,298
+864
| +2% | +$55.7K | 0.2% | 134 |
|
|
2020
Q4 | $2.59M | Sell |
44,434
-2,488
| -5% | -$150K | 0.18% | 134 |
|
|
2020
Q3 | $2.96M | Sell |
46,922
-967
| -2% | -$67.1K | 0.24% | 112 |
|
|
2020
Q2 | $3.69M | Buy |
47,889
+3,720
| +8% | +$285K | 0.31% | 99 |
|
|
2020
Q1 | $3.3M | Sell |
44,169
-923
| -2% | -$63.8K | 0.32% | 92 |
|
|
2019
Q4 | $2.93M | Sell |
45,092
-2,470
| -5% | -$161K | 0.22% | 119 |
|
|
2019
Q3 | $3.01M | Sell |
47,562
-1,609
| -3% | -$105K | 0.25% | 112 |
|
|
2019
Q2 | $3.32M | Buy |
49,171
+835
| +2% | +$54.9K | 0.28% | 101 |
|
|
2019
Q1 | $3.14M | Sell |
48,336
-2,353
| -5% | -$156K | 0.3% | 94 |
|
|
2018
Q4 | $3.65M | Buy |
50,689
+890
| +2% | +$62.2K | 0.38% | 81 |
|
|
2018
Q3 | $3.85M | Sell |
49,799
-92
| -0.2% | -$6.95K | 0.34% | 94 |
|
|
2018
Q2 | $3.53M | Buy |
49,891
+41
| +0.1% | +$2.9K | 0.33% | 97 |
|
|
2018
Q1 | $3.76M | Buy |
49,850
+1,032
| +2% | +$82K | 0.35% | 93 |
|
|
2017
Q4 | $3.5M | Buy |
48,818
+1,625
| +3% | +$123K | 0.32% | 98 |
|
|
2017
Q3 | $3.82M | Buy |
47,193
+2,151
| +5% | +$164K | 0.39% | 86 |
|
|
2017
Q2 | $3.19M | Sell |
45,042
-3,559
| -7% | -$237K | 0.34% | 97 |
|
|
2017
Q1 | $3.3M | Buy |
48,601
+492
| +1% | +$34.6K | 0.35% | 95 |
|
|
2016
Q4 | $3.44M | Sell |
48,109
-1,888
| -4% | -$140K | 0.39% | 86 |
|
|
2016
Q3 | $3.96M | Sell |
49,997
-670
| -1% | -$54.4K | 0.46% | 77 |
|
|
2016
Q2 | $4.23M | Buy |
50,667
+2,903
| +6% | +$258K | 0.51% | 69 |
|
|
2016
Q1 | $4.39M | Buy |
47,764
+2,583
| +6% | +$233K | 0.54% | 61 |
|
|
2015
Q4 | $4.57M | Sell |
45,181
-1,319
| -3% | -$137K | 0.58% | 56 |
|
|
2015
Q3 | $4.57M | Buy |
46,500
+2,167
| +5% | +$241K | 0.62% | 54 |
|
|
2015
Q2 | $5.19M | Sell |
44,333
-259
| -0.6% | -$28.3K | 0.65% | 49 |
|
|
2015
Q1 | $4.38M | Sell |
44,592
-1,945
| -4% | -$198K | 0.55% | 62 |
|
|
2014
Q4 | $4.39M | Buy |
46,537
+250
| +0.5% | +$25.9K | 0.55% | 65 |
|
|
2014
Q3 | $4.93M | Sell |
46,287
-446
| -1% | -$43.7K | 0.65% | 49 |
|
|
2014
Q2 | $3.88M | Sell |
46,733
-1,049
| -2% | -$81.7K | 0.5% | 69 |
|
|
2014
Q1 | $3.39M | Sell |
47,782
-1,022
| -2% | -$80.2K | 0.45% | 75 |
|
|
2013
Q4 | $3.67M | Buy |
48,804
+381
| +0.8% | +$26.5K | 0.52% | 69 |
|
|
2013
Q3 | $3.04M | Sell |
48,423
-857
| -2% | -$51.2K | 0.48% | 75 |
|
|
2013
Q2 | $2.53M | Buy |
+49,280
| New | +$2.57M | 0.42% | 82 |
|
Other funds holding GILD
Dowling & Yahnke's GILD Position: Q3 2022 in Review
Dowling & Yahnke increased its Gilead Sciences (GILD) stake by 4.8% in Q3 2022, buying an estimated $143K and bringing the position to 49,473 shares worth $3.05M. The position accounts for 0.14% of the portfolio, ranked #139.
Dowling & Yahnke first reported a position in GILD in Q2 2013 and has held it in 38 quarters since. The position peaked at $5.19M in Q2 2015. 1,603 funds tracked by Wall St. Rank hold GILD as of Q3 2022.
- Dowling & Yahnke held 49,473 shares of Gilead Sciences worth $3.05M as of Q3 2022.
- Dowling & Yahnke bought 2,269 Gilead Sciences shares in Q3 2022, an estimated $143K.
- Gilead Sciences made up 0.14% of Dowling & Yahnke's portfolio in Q3 2022, its #139 holding.
- Dowling & Yahnke first reported a position in Gilead Sciences in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Gilead Sciences position peaked at $5.19M in Q2 2015.
- 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.